PF-04447943 + donepezil

PF-04447943 + donepezil is a combination of two investigational and approved small molecule drugs. PF-04447943 is a potent and selective inhibitor of phosphodiesterase 9A (PDE9A), which is being investigated for its effect on cognitive functions by enhancing cyclic guanosine monophosphate (cGMP) signaling pathways in the brain. Donepezil is an acetylcholinesterase inhibitor, already approved and widely used to treat symptoms of Alzheimer's disease by increasing acetylcholine concentrations in the brain. This combination is being studied for potential synergistic cognitive benefits in Alzheimer's disease, targeting multiple neurochemical pathways involved in memory and cognition[1][8].